Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Patients and partners join forces to tackle fear of cancer recurrence

NCT ID NCT07234656

Knowledge-focused Sponsor: Brigitta Rasmussen Villumsen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at fear of cancer recurrence in people who had surgery for kidney cancer and their partners. Researchers are working with patients to create better ways to ask about and measure this fear. The goal is to improve follow-up care by understanding what matters most to patients and their loved ones.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand and address fear of cancer recurrence in kidney cancer survivors and their partners, improving follow-up care.
What could go wrong
This is an early, small observational study (105 participants) focused on developing and testing questionnaires, not testing a treatment. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients and partners who fullfil the in- and exclusion criteria and are consulting urologists at Aalborg University Hospital, Aarhus University Hospital and Gødstrup Hospital, Denmark

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Phase 1: * Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse * Partner/spouse to patients who fullfil the inclusion criteria * Patients have undergone surgery due to localized RCC (T1-T2-T3 tumor) * Time since surgery: 0-120 months * Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish * Patients/partners/spouses able to and willing to attend online project meetings or in person at Gødstrup Hospital. Phase 2: * Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse * Partner/spouse to patients who fullfill the inclusion criteria * Patients who have undergone surgery due to localized RCC (T1-T2-T3 tumor) * Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish * Able to receive digital communication from the hospital * Informed consent must be signed before answering Fear of Cancer Recurrence questions Exclusion Criteria: Both phases, both patients and partners/spouses: * Diagnosed with cognitive impairment * Untreated psychiatric disorders due to non-compliance Phase 2: • Patients and partners/spouses who were panelists in phase 1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fear of cancer recurrence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancerophobia kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fear of cancer recurrence Renal cell carcinoma (kidney cancer)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    RECRUITING

    Aalborg, 9000, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus, 8200, Denmark

  • Gødstrup Hospital

    RECRUITING

    Herning, 7400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.